Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12CDiscovery and characterization of JDQ443

RT @imsmd: Saskia Brachmann presenting promising data at #EACR2023 from KontRASt-01 trial of the covalent RAS G12C inhibitor JDQ443 and po…

RT @imsmd: Saskia Brachmann presenting promising data at #EACR2023 from KontRASt-01 trial of the covalent RAS G12C inhibitor JDQ443 and po…

RT @imsmd: Saskia Brachmann presenting promising data at #EACR2023 from KontRASt-01 trial of the covalent RAS G12C inhibitor JDQ443 and po…

Saskia Brachmann presenting promising data at #EACR2023 from KontRASt-01 trial of the covalent RAS G12C inhibitor JDQ443 and potential future directions: check out the initial report of the discovery/preclinical/early clinical charac of JDQ443 https://t.c